Publications - IR Sant Pau

Search

01/07/2025 Analytical Interference of Exemestane with Androstenedione Immunoassays

Giralt, M, Ferrer, R, Díaz-Troyano, N, Vega, B, Luque-Ramírez, M, Martínez, S, Fernández, B, Martínez, I, Fabregat, A, Urgell, E, Cardona, I, Casals, G, Escobar-Morreale, HF. Analytical Interference of Exemestane with Androstenedione Immunoassays. Annals of Laboratory Medicine. 2025; 45(4)DOI:10.3343/alm.2024.0362. PMID:40114653. IF:3.900(Q1/1D).

01/09/2024 Impaired high-density lipoprotein function and endothelial barrier stability in severe anaphylaxis

Fernandez-Bravo, S, Canyelles, M, Martín-Blázquez, A, Borràs, C, Nuñez-Borque, E, Palacio-García, L, Del Rio, PR, Betancor, D, Gómez-López, A, Brescó, MS, Laguna, JJ, Méndez-Barbero, N, Rotllan, N, Escolà-Gil, JC, Esteban, V. Impaired high-density lipoprotein function and endothelial barrier stability in severe anaphylaxis. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2024; 154(3)DOI:10.1016/j.jaci.2024.03.031. PMID:38718948. IF:11.200(Q1/1D).

01/08/2024 IN VITRO AND IN VIVO EFFECTS OF LIVER X RECEPTOR AND CHOLESTEROL LOADING IN VASCULAR SMOOTH MUSCULAR CELL-SPECIFIC REVERSE CHOLESTEROL TRANSPORT

Velasco, L, Querol, CB, Santos, D, Rotllan, N, Tondo, M, Camacho, M, Blanco-Vaca, F, Escolà-Gil, JC, Canyelles, M. IN VITRO AND IN VIVO EFFECTS OF LIVER X RECEPTOR AND CHOLESTEROL LOADING IN VASCULAR SMOOTH MUSCULAR CELL-SPECIFIC REVERSE CHOLESTEROL TRANSPORT. ATHEROSCLEROSIS. 2024; 395DOI:. PMID:. IF:5.700(Q1/1D).

01/08/2024 HDL PROTEOME ASSOCIATES WITH HEPATIC AND ADIPOSE TISSUE INSULIN RESISTANCE AND CHOLESTEROL EFFLUX CAPACITY IN METABOLIC SYNDROME PATIENTS

Grao-Cruces, E, Mocciaro, G, Marquez-Paradas, E, Santos-Mejias, A, Canyelles, M, Escola-Gil, JC, Martin-Rubio, ME, La Paz, SMD. HDL PROTEOME ASSOCIATES WITH HEPATIC AND ADIPOSE TISSUE INSULIN RESISTANCE AND CHOLESTEROL EFFLUX CAPACITY IN METABOLIC SYNDROME PATIENTS. ATHEROSCLEROSIS. 2024; 395DOI:. PMID:. IF:5.700(Q1/1D).

31/07/2024 Improvement of non-adherence and reduction of BP values in patients with difficult-to-treat hypertension: the ATHAN clinical trial

Oliveras, A, Vázquez, S, Vega, MV, Camps, C, Illana, FJ, Armario, P, Crespo, M, de la Sierra, A. Improvement of non-adherence and reduction of BP values in patients with difficult-to-treat hypertension: the ATHAN clinical trial. HYPERTENSION RESEARCH. 2024; DOI:10.1038/s41440-024-01748-x. PMID:39085464. IF:4.600(Q1/2D).

01/07/2024 Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice

Delgado-Lista, J, Mostaza, JM, Arrobas-Velilla, T, Blanco-Vaca, F, Masana, L, Pedro-Botet, J, Perez-Martinez, P, Civeira, F, Cuende-Melero, JI, Gomez-Barrado, JJ, Lahoz, C, Pinto, X, Suarez-Tembra, M, Lopez-Miranda, J, Guijarro, C. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice. Clinica E Investigacion En Arteriosclerosis. 2024; 36(4)DOI:10.1016/j.arteri.2024.03.002. PMID:38599943. IF:(Q/D).

17/06/2024 Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis

La Lhoëst, MTL, Martinez, A, Claudi, L, Garcia, E, Benitez-Amaro, A, Polishchuk, A, Piñero, J, Vilades, D, Guerra, JM, Sanz, F, Rotllan, N, Escolà-Gil, JC, Llorente-Cortés, V. Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis. Frontiers in Cardiovascular Medicine. 2024; 11DOI:10.3389/fcvm.2024.1381520. PMID:38952543. IF:2.900(Q2/4D).

01/06/2024 Apolipoproteins and Lipoproteins in Health and Disease 2.0

Rotllan, N, Escolà-Gil, JC. Apolipoproteins and Lipoproteins in Health and Disease 2.0. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(11)DOI:10.3390/ijms25116183. PMID:38892369. IF:4.900(Q1/3D).

01/06/2024 Quality assurance of add-on testing in plasma samples: stability limit for 29 biochemical analytes

Illana, FJ, García-Osuna, A, Sospedra, M, Ferrer, R, Martínez-Brú, C, Guiñón, L. Quality assurance of add-on testing in plasma samples: stability limit for 29 biochemical analytes. Biochemia Medica. 2024; 34(2)DOI:10.11613/BM.2024.020704. PMID:38665870. IF:1.800(Q3/6D).

01/06/2024 Inhibitory effects of LRP1-based immunotherapy on cardiac extracellular matrix biophysical alterations induced by hypercholesterolemia

Lhoëst, MTL, Samouillan, V, García, E, Amaro, AB, Dandurand, J, Dato, VA, Guerra, JM, Escolà-Gil, JC, Chiabrando, G, Enrich, C. Inhibitory effects of LRP1-based immunotherapy on cardiac extracellular matrix biophysical alterations induced by hypercholesterolemia. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).

29/05/2024 Decreased atherosclerosis and abdominal aortic aneurysm in mice deficient in polymeric immunoglobulin receptor

Pardo, IC, Botija, BP, Garcia, AG, Villanueva, LO, Folgado, IM, Raposo,, Mur, S, Robles,, Gil, JCE, Nunez, E, Sancho, D, Vazquez, J, Colio, LMB, Ramiro, A, Ventura, JLM. Decreased atherosclerosis and abdominal aortic aneurysm in mice deficient in polymeric immunoglobulin receptor. CARDIOVASCULAR RESEARCH. 2024; 120DOI:10.1093/cvr/cvae088.161. PMID:. IF:13.300(Q1/1D).

29/05/2024 Role of polymeric immunoglobulin receptor in glucose metabolism

Botija, MP, Pardo, IC, Garcia, AG, Villanueva, LO, Colio, LB, Ramiro, A, Gil, JCE, Ventura, JLM. Role of polymeric immunoglobulin receptor in glucose metabolism. CARDIOVASCULAR RESEARCH. 2024; 120DOI:10.1093/cvr/cvae088.192. PMID:. IF:13.300(Q1/1D).

01/01/2024 Hydroxytyrosol Induces Dyslipidemia in an ApoB100 Humanized Mouse Model

de las Hazas, MCL, del Saz-Lara, A, Cedó, L, Crespo, MC, Tomé-Carneiro, J, Chapado, LA, Macià, A, Visioli, F, Escola-Gil, JC, Dávalos, A. Hydroxytyrosol Induces Dyslipidemia in an ApoB100 Humanized Mouse Model. MOLECULAR NUTRITION & FOOD RESEARCH. 2024; 68(1)DOI:10.1002/mnfr.202300508. PMID:37933702. IF:4.200(Q1/3D).

14/12/2023 Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation

Martinez-Campanario, MC, Cortés, M, Moreno-Lanceta, A, Han, L, Ninfali, C, Domínguez, V, Andrés-Manzano, MJ, Farràs, M, Esteve-Codina, A, Enrich, C, Diaz-Crespo, FJ, Pintado, B, Escolà-Gil, JC, de Frutos, PG, Andrés, V, Melgar-Lesmes, P, Postigo, A. Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-43896-7. PMID:38097578. IF:14.700(Q1/1D).

01/11/2023 Characterization of add-on testing before and after automation at a core laboratory

García-Osuna, A, Muñoz, LG, Pallaruelo, MC, Usero, AM, Eduardo, BC, Ramos, JL, Canyelles, M, Brú, CM, Cámara, FJI. Characterization of add-on testing before and after automation at a core laboratory. Heliyon. 2023; 9(11)DOI:10.1016/j.heliyon.2023.e22096. PMID:38034602. IF:3.400(Q1/3D).

27/10/2023 Systems biology and data-driven machine learning-based models in personalized cardiovascular medicine

Hueso, M, Rotllan, N, Escolà-Gil, JC, Vellido, A. Systems biology and data-driven machine learning-based models in personalized cardiovascular medicine. Frontiers in Cardiovascular Medicine. 2023; 10DOI:10.3389/fcvm.2023.1320110. PMID:37965080. IF:2.800(Q2/4D).

12/10/2023 Periodic verification of results' comparability between several analyzers: Experience in the application of the EP31-A-IR guideline

Guiñón L., Illana F.J., Cuevas B., Canyelles M., Martínez-Bru C., García-Osuna Á.. Periodic verification of results' comparability between several analyzers: Experience in the application of the EP31-A-IR guideline. CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2023; 62(3)DOI:10.1515/cclm-2023-0994. PMID:37819627. IF:3.800(Q1/2D).

01/08/2023 Obesity-induced changes in cancer cells and their microenvironment: Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism

Lee-Rueckert, M, Canyelles, M, Tondo, M, Rotllan, N, Kovanen, PT, Llorente-Cortes, V, Escola-Gil, JC. Obesity-induced changes in cancer cells and their microenvironment: Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism. SEMINARS IN CANCER BIOLOGY. 2023; 93DOI:10.1016/j.semcancer.2023.05.002. PMID:37156344. IF:12.100(Q1/1D).

01/06/2023 "MiR-7 controls cholesterol biosynthesis through posttranscriptional regulation of DHCR24 expression"

Frutos, MFD, Pardo-Marques, V, Torrecilla-Parra, M, Rada, P, Perez-Garcia, A, Martin-Martin, Y, de la Pena, G, Gomez, A, Toledano-Zaragoza, A, Gomez-Coronado, D, Casarejos, MJ, Solis, JM, Rotllan, N, Pastor, O, Ledesma, MD, Valverde, AM, Busto, R, Ramirez, CM. "MiR-7 controls cholesterol biosynthesis through posttranscriptional regulation of DHCR24 expression". Biochimica et Biophysica Acta-Gene Regulatory Mechanisms. 2023; 1866(2)DOI:10.1016/j.bbagrm.2023.194938. PMID:37086967. IF:2.600(Q3/6D).

11/05/2023 Inhibitory Effects of LRP1-Based Immunotherapy on Cardiac Extracellular Matrix Biophysical Alterations Induced by Hypercholesterolemia

Samouillan, V, Garcia, E, Benitez-Amaro, A, Lhoest, MTLC, Dandurand, J, Dato, VA, Guerra, JM, Escola-Gil, JC, Chiabrando, G, Enrich, C, Llorente-Cortes, V. Inhibitory Effects of LRP1-Based Immunotherapy on Cardiac Extracellular Matrix Biophysical Alterations Induced by Hypercholesterolemia. JOURNAL OF MEDICINAL CHEMISTRY. 2023; 66(9)DOI:10.1021/acs.jmedchem.2c02103. PMID:37116069. IF:6.900(Q1/1D).